论文部分内容阅读
检测乳癌复发及监测乳癌治疗反应,确实需要较敏感而特异的血清学指标。初步临床证据表明,对于乳腺癌的随访,CA15-3较 CEA更为敏感。在本研究中,作者评价了 CA15-3的敏感性和特异性及对乳癌病人随访的作用。作者分别从177例原发性乳癌患者及58例年龄相仿的非恶性乳腺疾病病人获取血清标本。所有病人均为芬兰坦派勒中心医院1981～1985年间的手术病例。乳癌分期依据 TNM 分类,血清 CA15-3采用放免法测定,其正常上限值为38U/ml。结果:术前分别有7%Ⅰ期、17%Ⅱ期、
Detection of recurrence of breast cancer and monitoring of breast cancer treatment response do require sensitive and specific serological markers. Preliminary clinical evidence suggests that CA15-3 is more sensitive than CEA for breast cancer follow-up. In this study, the authors assessed the sensitivity and specificity of CA15-3 and its role in the follow-up of breast cancer patients. The authors obtained serum samples from 177 patients with primary breast cancer and 58 patients with age-matched non-malignant breast disease. All patients were surgical cases between 1981 and 1985 at the Tanzania Templar Central Hospital. Breast cancer staging was based on TNM classification. Serum CA15-3 was measured by radioimmunoassay. The normal upper limit value was 38 U/ml. Results: There were 7% phase I and 17% phase II before surgery.